| Noonan Syndrome

Norditropin vs Sogroya

Side-by-side clinical, coverage, and cost comparison for noonan syndrome.

Deep comparison between: Norditropin vs Sogroya with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsSogroya has a higher rate of injection site reactions vs Norditropin based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Sogroya but not Norditropin, including UnitedHealthcare

Category

Norditropin

Sogroya

At A Glance

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

RouteSC injection

FrequencyOnce weekly

ClassGrowth hormone analog

Indications

Noonan Syndrome
Turner Syndrome
Prader-Willi Syndrome

Somatotropin deficiency
Noonan Syndrome

Dosing

Pediatric GHD 0.17-0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Noonan Syndrome Up to 0.46 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Turner Syndrome, SGA, ISS Up to 0.47 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Adult GHD (non-weight-based) Initiate at approximately 0.2 mg/day SC (range 0.15-0.3 mg/day); increase every 1-2 months by 0.1-0.2 mg/day based on clinical response and IGF-1 concentrations.

Adult GHD (weight-based) Initiate at 0.004 mg/kg/day SC; increase to a maximum of 0.016 mg/kg/day; not recommended for obese patients.

Somatotropin deficiency (pediatric) 0.16 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.

Noonan Syndrome, SGA, ISS 0.24 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.

Somatotropin deficiency (adult) Initiate 1.5 mg SC once weekly; titrate every 2-4 weeks by 0.5-1.5 mg to desired response; maximum 8 mg once weekly.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Active malignancy
Hypersensitivity to somatropin or any excipient of NORDITROPIN
Active proliferative or severe non-proliferative diabetic retinopathy
Pediatric patients with closed epiphyses

Acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Hypersensitivity to somapacitan-beco or any excipient
Pediatric patients with closed epiphyses
Active malignancy
Active proliferative or severe non-proliferative diabetic retinopathy
Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment

Drug Interactions

267View drug interactions

254View drug interactions

Adverse Reactions

Most common (>=5%, adult onset GHD) Peripheral edema, edema, arthralgia, leg edema, myalgia, non-viral infection, paraesthesia, skeletal pain, headache, bronchitis, flu-like symptoms, hypertension, gastroenteritis, increased sweating, abnormal glucose tolerance, laryngitis, type 2 diabetes mellitus

Serious Increased mortality in acute critical illness, sudden death in pediatric PWS patients, neoplasms, intracranial hypertension, severe hypersensitivity reactions, fluid retention, slipped capital femoral epiphysis, pancreatitis

Postmarketing Anaphylactic reactions, angioedema, increase in cutaneous nevi, hypothyroidism, gynecomastia, hyperglycemia, osteonecrosis, increased blood alkaline phosphatase, decreased serum T4, pancreatitis, leukemia

Most common (>=5%) Nasopharyngitis, respiratory tract infection, pyrexia, headache, pain in extremity, injection site reaction, diarrhea, vomiting, cough, ear infection

Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasm risk, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipohypertrophy/lipoatrophy, sudden death in Prader-Willi syndrome patients

Postmarketing Osteonecrosis in pediatric patients

Pharmacology

Recombinant human growth hormone (somatropin) binds to dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins including IGF-1, IGFBP-3, and acid-labile subunit, which stimulate chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal linear growth via effects on epiphyses of long bones.

Somapacitan-beco is a human growth hormone (hGH) analog that binds to a dimeric GH receptor in the cell membrane of target cells, triggering intracellular signal transduction and pharmacodynamic effects mediated both directly and through IGF-1 produced in the liver.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Norditropin